[Clinical results of selective estrogen receptor modulators (SERM)].
The SERMs (selective estrogen receptor modulators) are a new class of molecules that bind to the estrogen receptor, resulting in an estradiol agonist or antagonist response according to the target tissue. Raloxifene, a new SERM, has been shown to prevent postmenopausal bone loss, to reduce the risk of vertebral fractures in osteoporotic women, to decrease serum cholesterol and its LDL fraction, and to reduce significantly the risk of breat cancer. Raloxifene is available in France for the prevention of post-menopausal osteoporosis.
Delmas
P D
PD
Service de rhumatologie, Hôpital Edouard-Herriot, Lyon, France.
D001842:Bone and Bones / Q000187:drug effects; D001940:Breast / Q000187:drug effects; D002318:Cardiovascular Diseases; D005260:Female; D006801:Humans; D008074:Lipoproteins; D010024:Osteoporosis / Q000188:drug therapy; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D014599:Uterus / Q000187:drug effects
D008074:Lipoproteins; D020845:Selective Estrogen Receptor Modulators